Last updated: March 13, 2026
What is NDC 63646-0010?
NDC 63646-0010 is a prescription drug marketed under the name Baxdela (delafloxacin). It is an antibiotic indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated intra-abdominal infections (cIAI). Approved by the FDA in June 2017, Baxdela is part of the fluoroquinolone class of antibiotics.
Market Size and Segments
Overall Antibiotics Market
The global antibiotic market was valued at approximately $47 billion in 2022, with an expected compound annual growth rate (CAGR) of 3.8% through 2030.[1]
Fluoroquinolones Segment
Fluoroquinolones, including delafloxacin, represent a subset of antibiotics valued at around $4.5 billion in 2022. The segment is expected to grow at a CAGR of 3.5% to 4.2%, driven by increasing bacterial resistance concerns and new drug approvals.[2]
Niche Market for Baxdela
Baxdela specifically targets resistant bacterial infections, especially those strains resistant to other fluoroquinolones. Its primary market includes top-tier hospitals and outpatient clinics focusing on severe infections caused by resistant pathogens like MRSA.
Key Market Drivers
- Rise in antibiotic-resistant bacteria.
- Increasing prevalence of skin infections and intra-abdominal infections.
- Limited competition; no direct generic equivalents due to patent protections.
Market Competition
Major Competitors
- Ciprofloxacin (Bayer)
- Levofloxacin (Sanofi)
- Moxifloxacin (Bayer)
- Delafloxacin (Baxdela) as a first-in-class for its indication
Patent Status and Exclusivity
Baxdela's patent protection extends until approximately 2030, with no generic competitors currently authorized by the U.S. Patent and Trademark Office (USPTO). This exclusivity supports pricing power during the patent life.
Historical Pricing Trends
Initial Launch Price
- Fevered initial wholesale acquisition cost (WAC): approximately $350 per 250 mg vial.
- Typical course (or 10-day treatment): around $1,500 - $2,000 per patient.
Price Movements
- No substantial price reductions observed since launch.
- Insurers have negotiated discounts, but the list price remains stable due to patent protection and limited competition.
Price Projections (Next 5 Years)
| Year |
Estimated WAC per Course |
Remarks |
| 2023 |
$1,500 - $2,000 |
Current list pricing |
| 2024 |
$1,500 - $2,000 |
No significant discounts expected |
| 2025 |
$1,400 - $1,900 |
Slight downward pressure from payer negotiations |
| 2026 |
$1,350 - $1,850 |
Patent exclusivity sustains pricing |
| 2027 |
$1,300 - $1,800 |
Near patent expiration considerations |
Financial Outlook
Revenue Estimates
- Assuming conservative market penetration:
- Year 1 (2023): $200 million
- Year 3 (2025): $300 million
- Year 5 (2027): $400 million
Market uptake is influenced by higher hospital adoption rates and expanding indications.
Pricing Impact
- Price stability maintained until patent expiration.
- Post-expiry, potential generic entry could reduce prices by 40-60%, impacting revenue.
Regulatory and Policy Influences
- Antibiotic stewardship policies aim to optimize use, potentially constraining growth.
- Off-label uses are limited and regulated.
- International markets exhibit variable approval timelines and pricing pressures.
Risks and Opportunities
Risks
- Patent expiration leading to generics.
- Emerging resistance reducing antibiotic efficacy.
- Stringent healthcare cost controls.
Opportunities
- Expanding into new infection types.
- Combination therapy development.
- Growth in outpatient settings.
Summary
NDC 63646-0010 (Baxdela) is positioned within a niche of resistant bacterial infection treatments, with limited competition and patent exclusivity extending into the late 2020s. Pricing remains stable, with modest downward pressure expected near patent expiration. Revenue projections suggest moderate growth aligned with increasing bacterial resistance and hospital adoption, contingent on regulatory developments and competitive dynamics.
Key Takeaways
- Baxdela's current price remains stable at around $1,500 per course.
- Market penetration is limited but growing, targeting resistant bacterial infections.
- Patent protection shields pricing power until 2030, after which generic entry could significantly lower prices.
- Revenue growth depends heavily on hospital adoption rates and expansion into new indications.
- Increasing resistance to existing antibiotics is a core market driver.
FAQs
1. What factors influence Baxdela's market penetration?
Market penetration depends on infection prevalence, hospital prescribing habits, antibiotic resistance patterns, and competition from existing fluoroquinolones.
2. How does patent expiration affect pricing?
Patent expiration typically leads to generic entry, which can reduce prices by up to 60%, impacting revenue and market share.
3. Are there any approved generics for Baxdela?
As of 2023, no generics have received approval, due to patent protections until approximately 2030.
4. What is the potential for international expansion?
Market access varies by country, with regulatory submissions ongoing in Europe and Asia. Pricing pressures and approval timelines differ regionally.
5. How could resistance trends impact Baxdela's future?
Rising resistance may lead to lower efficacy, reducing demand and potentially prompting formulary restrictions.
References
[1] MarketsandMarkets. (2022). Antibiotics Market. Retrieved from https://www.marketsandmarkets.com
[2] Grand View Research. (2022). Fluoroquinolones Market Size. Retrieved from https://www.grandviewresearch.com
